By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eiger Biopharma 



Palo Alto  California    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS



Segment
Start Up





Company News
Eiger Biopharma Announces Completion Of Enrollment Of Phase 2 LOWR HDV - 3 (Lonafarnib With Ritonavir In Hepatitis Delta Virus - 3) Study At NIH 1/19/2016 6:15:34 AM
Eiger Biopharma Announces First Patient Dosed In Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study At Hannover Medical School In Hannover, Germany 1/6/2016 8:03:37 AM
Eiger Biopharma Announces Notice Of Allowance For U.S. Patent Covering Bestatin (Ubenimex) For The Treatment Of Pulmonary Arterial Hypertension 12/15/2015 6:23:12 AM
Eiger Biopharma Granted Orphan Drug Status For Ubenimex In Pulmonary Arterial Hypertension 11/30/2015 6:35:49 AM
Eiger Biopharma Announces Acquisition Of Exclusive License To Program For Treatment Of Post-Bariatric Hypoglycemia From Stanford University 11/12/2015 7:49:43 AM
Eiger Biopharma Announces Acquisition Of Exclusive License To Lymphedema Program From Stanford University 11/11/2015 6:39:09 AM
Eiger Biopharma Announces Acquisition Of Exclusive License To Pulmonary Arterial Hypertension (PAH) Program From Stanford University 11/10/2015 6:19:39 AM
Eiger Biopharma Announces License Agreement With Nippon Kayaku Co., Ltd. To Develop Bestatin (ubenimex) For Inflammatory Diseases Involving LTB4 11/9/2015 7:22:26 AM
Eiger Biopharma Appoints Thomas J. Dietz, Ph.D. To The Eiger Board Of Directors 10/22/2015 11:36:36 AM
Eiger Biopharma Appoints Eduardo Martins, M.D., Ph.D., As Senior Vice President, Liver And Infectious Diseases Drug Development 10/20/2015 11:29:04 AM
123
//-->